The newest FDA-approved combination therapy is elexacaftor/tezacaftor/ivacaftor (ETI), the first triple combination therapy, for patients who are 12 years and older that have CF with at least one F508del mutation in the CFTR protein. The gene discussed is CFTR; the disease is cystic fibrosis.